USPTO 2015–2025 USPTO PatentsView US Corporation

Recursion Pharmaceuticals, Inc.

USPTO PatentsView assignee record — 30 granted patents across 22 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G06F (ELECTRIC DIGITAL DATA PROCESSING).

30
Total patents granted
22
CPC technology areas
18.1
Avg claims per patent
+1300%
5-year filing velocity

Portfolio overview

Recursion Pharmaceuticals, Inc. has been granted 30 US utility patents between 2018 and 2025, placing Recursion Pharmaceuticals, Inc. at rank #10,441 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.1 claims per patent with primary concentration in G06F (ELECTRIC DIGITAL DATA PROCESSING). As a US Corporation, Recursion Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 55.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 28 grants, compared with 2 in the 2015–2019 window — a +1300% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Recursion Pharmaceuticals, Inc.'s 18.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Recursion Pharmaceuticals, Inc. against peers pursuing similar technology classes.

How does Recursion compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Recursion holds 30 patents — placing it at rank #10,441 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2018–2025

0246810 20182019202020212022202320242025 5
USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table
Recursion Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2018 1 3.3%
2019 1 3.3%
2020 1 3.3%
2021 5 16.7%
2022 4 13.3%
2023 4 13.3%
2024 9 30.0%
2025 5 16.7%

Which technologies does Recursion Pharmaceuticals, Inc. patent most?

Top 15 of 22 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Accelerating

Where it ranks

Overall rank by patents

#10,441

Across all tracked assignees

Innovation Score

55.5 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Recursion Pharmaceuticals, Inc. hold?
Recursion Pharmaceuticals, Inc. holds 30 US granted patents filed between 2018 and 2025, spanning 22 technology areas.
What is Recursion Pharmaceuticals, Inc.'s Innovation Score?
Recursion Pharmaceuticals, Inc. has an Innovation Score of 55.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Recursion Pharmaceuticals, Inc. focus on?
Recursion Pharmaceuticals, Inc.'s top technology area is G06F (ELECTRIC DIGITAL DATA PROCESSING) with 13 patents. The company has filed patents in 22 CPC subclasses total.
Is Recursion Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Recursion Pharmaceuticals, Inc.'s recent filing velocity is +1300% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Recursion Pharmaceuticals, Inc.'s patents?
Recursion Pharmaceuticals, Inc.'s patents average 18.1 claims each. This falls within the standard range, providing solid legal coverage.
How is the Recursion Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope